Smarcd1

Total cell proteins were lysed in radioimmunoprecipitation assay buffer containing protease inhibitors. All protein samples were separated on 10% sodium dodecyl sulphate–polyacrylamide gels and electro‐transferred to Hybond membranes (Amersham, Munich, Germany) at the concentrations of 1 mg/ml. Fat‐free milk (5%) was used to block the membranes for 2 hrs at room temperature. Subsequently, primary antibodies against CDK1, SMARCD1, CCND1, P70S6K, MMP2 and Bcl‐xL (Proteintech, Chicago, IL, USA) were incubated with the blots overnight at 4°C. Then the membranes were incubated with the secondary antibody for 2 hrs at room temperature after removing the primary antibodies and washed three times with TBST. An enhanced chemiluminescence system was used to visualize the proteins following the manufacturer's protocol (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Adult male C57/BL6 mice were sacrificed at 8 weeks after TAC or sham surgery and heart samples were collected. Proteins were then extracted from these LV of hearts and assessed by western blotting analysis. The primary antibodies used were antibodies against P70/S6K, FGFR3, GAPDH (Bioworld Technology, Inc.), phosphor-P70/S6K and Caspase 3 (Cell Signaling Technology, Inc.), mTOR (Abcam, Inc), α-smooth muscle actin (α-SMA) (Abcam, Inc), atrial natriuretic peptide (ANP) (Abcam, Inc), SMARCD1 and SMARCA5 (ProteintechGroup, Inc.).